Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. The company is headquartered in Fort Worth, Texas and currently employs 141 full-time employees. The company markets several products for surgical and chronic wound care applications and has multiple products in its pipeline. Its surgical products, CellerateRX Surgical, TEXAGEN, BiFORM, ACTIGEN, ALLOCYTE, ALLOCYTE Plus Advanced Viable Bone Matrix (ALLOCYTE Plus), BIASURGE, FORTIFY TRG Tissue Repair Graft (FORTIFY TRG), and FORTIFY FLOWABLE Extracellular Matrix (FORTIFY FLOWABLE) are used in a range of surgical specialties to help promote patient healing and reduce the risk of complications. CellerateRX Surgical products, TEXAGEN products, FORTIFY TRG and FORTIFY FLOWABLE are used in specialties, including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, and others.
Mr. Seth Yon is the President of Sanara Medtech Inc, joining the firm since 2025.
What is the price performance of SMTI stock?
The current price of SMTI is $18.99, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Sanara Medtech Inc?
Sanara Medtech Inc belongs to Health Care industry and the sector is Health Care
What is Sanara Medtech Inc market cap?
Sanara Medtech Inc's current market cap is $174.1M
Is Sanara Medtech Inc a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Sanara Medtech Inc, including 2 strong buy, 5 buy, 1 hold, 0 sell, and 2 strong sell